| Male (n = 1348) | Female (n = 385) | P-value |
---|---|---|---|
Age (years) | 63.6 ± 11.1 | 67.5 ± 11.5 | <0.01a |
Body mass index (kg/m2) | 24.5 ± 3.2 | 24.0 ± 4.3 | 0.02a |
Hypertension | 72.6Â % | 75.1Â % | 0.36 |
Diabetes mellitus | 41.5Â % | 31.4Â % | <0.01a |
Dyslipidemia | 70.5Â % | 70.1Â % | 0.89 |
Family history of ischemic heart disease | 20.0Â % | 13.2Â % | <0.01a |
Smoking | 53.6Â % | 47.6Â % | <0.01a |
History of coronary revascularization (PCI or CABG) | 31.2Â % | 15.6Â % | <0.01a |
Total cholesterol (mg/dl) | 187.1 ± 34.8 | 202.7 ± 36.8 | <0.01a |
Triglycerides (mg/dl) | 151.8 ± 99.9 | 130.3 ± 77.6 | <0.01a |
Low-density lipoprotein cholesterol (mg/dl) | 109.8 ± 30.3 | 115.6 ± 32.2 | <0.01a |
High-density lipoprotein cholesterol (mg/dl) | 48.8 ± 14.3 | 61.3 ± 19.4 | <0.01a |
Hemoglobin A1c (%) | 6.3 ± 1.1 | 6.1 ± 1.0 | 0.02a |
Serum creatinine (mg/dl) | 0.93 ± 0.29 | 0.71 ± 0.23 | <0.01a |
Estimated glomerular filtration rate (ml/min/1.73 m2) | 68.8 ± 17.4 | 68.4 ± 18.7 | 0.72 |
EPA (μg/dl) | 73.7 ± 43.2 | 74.4 ± 47.0 | 0.76 |
EPA/AA | 0.50 ± 0.31 | 0.46 ± 0.29 | 0.01a |
DHA (μg/dl) | 141.8 ± 52.5 | 149.0 ± 53.2 | 0.01a |
DHA/AA | 0.96 ± 0.40 | 0.92 ± 0.33 | 0.06 |
DGLA (μg/dl) | 32.7 ± 12.5 | 35.0 ± 11.5 | <0.01a |
AA (μg/dl) | 154.4 ± 51.3 | 167.8 ± 41.3 | <0.01a |
Statins | 53.0Â % | 53.2Â % | 0.95 |
Antiplatelet agents | 67.9Â % | 44.7Â % | <0.01a |
Renin angiotensin system inhibitors (ACE-I and ARB) | 50.7Â % | 50.6Â % | 1.00 |
Calcium channel blockers | 44.4Â % | 50.1Â % | 0.04a |
Beta blockers | 41.7Â % | 27.8Â % | <0.01a |
Hypoglycemic agents | 22.0Â % | 17.9Â % | 0.08 |